Sandbox:DN
| Class I |
| "1.Anticoagulation with a VKA and international normalized ratio (INR) monitoring is recommended in patients with a mechanical prosthetic valve.(Level of Evidence: A)" |
| "2. Anticoagulation with a VKA to achieve an INR of 2.5 is recommended in patients with a mechanical AVR (bileaflet or current-generation single tilting disc) and no risk factors for thromboembolism.(Level of Evidence: B)" |
| "3. Anticoagulation with a VKA is indicated to achieve an INR of 3.0 in patients with a mechanical AVR and additional risk factors for thromboembolic events (AF, previous thromboembolism, LV dys- function, or hypercoagulable conditions) or an older-generation mechanical AVR (such as ball-in-cage).(Level of Evidence: B)" |
| "4. Anticoagulation with a VKA is indicated to achieve an INR of 3.0in patients with a mechanical MVR.(Level of Evidence: B)" |
| "5. Aspirin 75 mg to 100 mg daily is recommended in addition to anticoagulation with a VKA in patients with a mechanical valve prosthesis.(Level of Evidence: A)" |
| Class IIa |
| "1. Aspirin 75 mg to 100 mg per day is reasonable in all patients with a bioprosthetic aortic or mitral valve. (Level of Evidence: B)" |
| "2. Anticoagulation with a VKA is reasonable for the first 3 months after bioprosthetic MVR or repair to achieve an INR of 2.5. (Level of Evidence: C)" |
| Class IIb |
| "1. Anticoagulation, with a VKA, to achieve an INR of 2.5 may be reasonable for the first 3 months after bioprosthetic AVR.(Level of Evidence: B)" |
| "2. Clopidogrel 75 mg daily may be reasonable for the first 6 months after TAVR in addition to life-long aspirin 75 mg to 100 mg daily. (Level of Evidence: C)" |
| Class III (Harm) |
| "1. Anticoagulant therapy with oral direct thrombin inhibitors or anti-Xa agents should not be used in patients with mechanical valve prostheses (Level of Evidence: B)" |